These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Influenza vaccine with squalene adjuvant: new preparation. No better than available products. Prescrire Int; 2004 Dec; 13(74):206-8. PubMed ID: 15599987 [TBL] [Abstract][Full Text] [Related]
24. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093 [TBL] [Abstract][Full Text] [Related]
25. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647 [TBL] [Abstract][Full Text] [Related]
30. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662 [TBL] [Abstract][Full Text] [Related]
31. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470 [TBL] [Abstract][Full Text] [Related]
32. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Del Giudice G; Stittelaar KJ; van Amerongen G; Simon J; Osterhaus AD; Stöhr K; Rappuoli R Sci Transl Med; 2009 Dec; 1(12):12re1. PubMed ID: 20371459 [TBL] [Abstract][Full Text] [Related]
33. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638 [TBL] [Abstract][Full Text] [Related]
34. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR; JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210 [TBL] [Abstract][Full Text] [Related]
36. Avian influenza. Preaching against the pandemic. Enserink M Science; 2005 Oct; 310(5747):429. PubMed ID: 16239456 [No Abstract] [Full Text] [Related]
37. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Song JY; Cheong HJ; Tsai TF; Chang HA; Choi MJ; Jeon JH; Kang SH; Jeong EJ; Noh JY; Kim WJ Vaccine; 2015 Aug; 33(36):4647-52. PubMed ID: 25980426 [TBL] [Abstract][Full Text] [Related]
40. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? O'Hagan DT; Wack A; Podda A Clin Pharmacol Ther; 2007 Dec; 82(6):740-4. PubMed ID: 17971820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]